Cultured skin fibroblasts from patients with Niemann-Pick disease Types A and B show an almost total deficiency in sphingomyelinase activity in vitro (1). Cells from patients with the juvenile neuronopathic form of Niemann-Pick disease Type C, however, display either a moderate attenuation of enzyme activity or have normal activity (1 1, 15, 16, 21) . However, although the residual activity in Niemann-Pick disease Type A and B cells is similar, the latter are clearly capable of metabolizing exogenous sphingomyelin, albeit at a significantly reduced rate (2, 13) ; in contrast, Niemann-Pick disease Type A cells are unable to degrade sphingomyelin added to the culture medium. These results suggest that subtle differences may exist between the abnormal enzymes in these two variant forms of the disorder but that the assay conditions used may not be suitable for the Received August IS, 1983; accepted April 10, 1984. detection of these differences in vitro. One possible explanation is that the nonionic detergent Triton X-100, which has been included in most in vitro assay systems, appears to interact with the enzyme, thereby altering somy of its physicochemical properties (3, 12) . It was thus considered likely that the presence of Triton would mask any differences in the mutant enzyme activities in Niemann-Pick Type A and B cells. We have recently developed an in vitro assay for sphingomyelinase activity based on the use of sphingomyelin liposomes rather than Triton lipid micelles as substrate (18, 20) . In this communication, we report on the results of assays performed under these conditions, and in the presence of a natural protein activator isolated from Gaucher spleen. Our data indicate that Niemann-Pick disease Type B and C, in contrast to Niemann-Pick disease Type A, cells respond to activator in an essentially normal fashion. In addition, our data do not support the view that Niemann-Pick Type C results from a deficiency in activator protein ( 1, 7). Cell culture. Unless stated otherwise in the text, skin fibroblasts were cultured in basal Eagle's medium containing 10% fetal calf serum until confluent and were then harvested. For some experiments, the medium from confluent cells was replaced with MCDB-104 medium (10) and the cells were maintained in the absence of fetal calf serum for 2-3 wk before harvesting. Cells were harvested by trypsinization and were then suspended in 0.25 M sucrose by sonicating for 10 s at 4" C with an Ystrom ultrasonicator. The sonicated suspensions were used for all enzyme studies; the protein concentration of these suspensions assayed as described by Bradford (5) varied from 1-4 mg/ml.
MATERIALS AND METHODS

Cultured
Sphingomyelinase assays. All assays were performed with liposomes of [methyl-14C] sphingomyelin prepared as follows.
['4C]Sphingomyelin (800,000 dpm, 5 1 mCi/mmol) and unlabeled bovine brain sphingomyelin (800 nmol) were suspended in 800 p1 water by ultrasonication for 25-30 min at room temperature until the suspension became clear. Reaction mixtures contained an aliquot of this suspension (10 pl), acetate buffer pH 3.8 or 4.2 (50 mM), fibroblast homogenate (20-50 pg protein), and activator protein (0-10 pg) in a final incubation volume of 100 p1. For pH versus activity studies, the buffers used were 50 mM acetate (pH 3.6-5.0 inclusive) and 50 mM Trismaleate (pH 5.5-8.5 inclusive). Incubation mixtures were incubated for 2 h at 37" C. Released [14C]phosphorylcholine was measured as described by Poulos and Beckman (1 7).
Preparation of activator. Activator was isolated from Gaucher spleen as described by Peters et al. (14) with some modifications (20) . For some experiments, activator which had been purified up to and including the DE-52 cellulose step was used in assays (activator preparation A). In other cases, the purification procedure was continued up to and including the Sephacryl G-200 POULOS column chromatography step as described (20) . Active fractions from the Sephacryl G-200 gel filtration were pooled, dialyzed exhaustively against water at 4" C, and then freeze-dried. The residue was then redissolved in 10 mM Tris-HC1 buffer, pH 7.0, containing 20% glycerol to give a final protein concentration of 1-2 mg/ml. Aliquots of this solution were also used as a source of activator and are referred to in the text as activator preparation B. Fibroblast protein (mg/ml) Fig. 2 . Activity of sphingomyelinase as a function of fibroblast protein concentration. Sphingomyelinase activity was measured in homogenates from two separate normal fibroblast lines as described in the text. 
RESULTS
Normal fibroblasts grown in basal Eagle's medium containing 10% fetal calf serum show two pH optima for the hydrolysis of sphingomyelin liposomes, one at pH 4.2-4.4 and the other at pH 7.5-8.5. Under the same conditions, a similar pH versus activity profile is shown by fibroblasts from patients with the early and late onset forms of Niemann-Pick disease Type C (Fig.  1) . Niemann-Pick Type A and B fibroblasts, however, were deficient at both pH optima, although considerable activity was detected in some of these lines. The specific activities of normal as well as mutant cell lines varied significantly according to the cell culture employed. Activities within individual cultures of both Niemann-Pick Type A and B fibroblasts, for example, at times approached 50% of the activity shown by normal cells (Table 2) . A major cause of this variability seemed to relate to the degree of confluence of the cells, very confluent cells showing greater activity.
The specific activity of the enzyme also varied according to the incubated protein concentration (Fig. 2) . Because of the nonlinearity of the reaction, a constant fibroblast protein concentration (0.40-0.50 mg/ml) was employed for all assays.
When normal fibroblasts were maintained in MCDB-104 me-dium devoid of fetal calf serum (see "Materials and Methods") change in the activity and the pH optimum was observed for their acidic sphingomyelinase activity increased markedly; con-fibroblasts from the adult (SF 1172, Fig. 1B) and early onset comitantly, the pH optimum decreased significantly from pH forms of Niemann-Pick disease Type C. Under these conditions, 4.2-4.4 (Fig. 1A) to pH 3.8-4.0 (Fig. 1B) . A corresponding the acidic sphingomyelinase activity of Niemann-Pick Type B but not Type A fibroblasts also increased, but to a lesser degree ( Table 2 ). The increase in activity observed in fibroblasts cultured in MCDB-104 medium was not confined to sphingomyelinase alone as it was also noted for a number of other lysosomal enzymes including P-galactocerebrosidase, 0-galactosidase, and acid-phosphatase.
Addition of the purified activator isolated from Gaucher spleen to incubation mixtures stimulated a dose-dependent increase in activity of the acidic sphingomyelinase. Fibroblasts from patients with the neonatal, early onset and late onset variant forms of Niemann-Pick disease Type C responded to activator in an identical fashion (Fig. 3) . Figure 4 , A and B, shows the response to activator of cells from two different subcultures of NiemannPick disease Types A and B. Residual activity in Type B fibroblasts varied in its response to activator both according to the cell line and to the subculture employed. Sphingomyelinase activity of Niemann-Pick Type A fibroblasts, however, responded poorly to activator in both subcultures tested. This apparent differentiation of the neuronopathic and non-neuronopathic forms of Niemann-Pick disease was more pronounced when the response to activator was studied in cells maintained in MCDB-104 medium (Fig. 5) . The acidic sphingomyelinase activity in Niemann-Pick Type B fibroblasts grown under these conditions was clearly more responsive to activator than that present in Type A fibroblasts.
DISCUSSION
Our data show clearly that sphingomyelinase activity can be detected in cultured skin fibroblasts from normal individuals when the substrate is prepared in a liposomal form and the enzyme activity is measured in the absence of detergents. Moreover, activity can be observed even in extracts from patients with Niemann-Pick disease Types A and B, activities ranging from approximately 0.08 to 0.5 nmol/h/mg protein. These values represent 10-50% of the activity detected in control cell lines. The relatively high degree of residual activity is somewhat surprising particularly in view of the low activity observed when assays are performed in the presence of detergents such as Triton X-100 (17) . The most likely explanation is that this activity is not due to the action of a lysosomal sphingomyelinase but rather results from an attack by a nonspecific phosphodiesterase such as that, for example, which cleaves bis (4-methylumbelliferyl) phosphate in the absence of Triton X-100 (4). The proportionally much greater stimulation of normal as opposed to both Type A and B fibroblast sphingomyelinase activities supports this view. Maintenance of cells in MCDB-104 medium devoid of fetal calf serum induces a marked increase in activity of a number of lysosomal enzymes and concomitantly leads to the increase in individual cells of vacuoles also suggesting an increase in lysosoma1 activity (unpublished results). The data shown in Figures  3 and 4 demonstrate that the activity present in normal, Niemann-Pick Type B, and Niemann-Pick Type C cells is stimulated quite significantly by purified Gaucher spleen activator. The two Niemann-Pick Type A cell lines examined, on the other hand, responded poorly, suggesting that the residual activity differs in some way from that found in the other cell lines. In the presence of activator, the residual Niemann-Pick Type B sphingomyelinase activity is stimulated to values which approach those shown by normal cells (i.e. when measured in the absence of activator) indicating that the in vivo activity may be sufficient to catabolize a sizeable proportion of the cellular sphingomyelin, providing endogenous stores of activator are elevated. These results confirm the apparent ability of fibroblasts, in culture, to degrade exogenous sphingomyelin (2, 13) . The accumulation of sphingomyelin in the liver and spleen of Type B patients may thus be explained by postulating that the attenuated enzyme activity cannot cope in those tissues, such as liver and spleen, in which there is a rapid turnover of membrane lipids. The data shown in Figure 4 suggest that the degree of residual sphingomyelinase activity varies even within patients with Niemann-Pick disease Type B and may ultimately explain why some patients present with hepatosplenomegaly very early in life, while others may not present till much later (6, 19) .
It is not known, at present, why the residual activities in Type A and B fibroblasts differ in their response to activator. In an analogous disease state, i.e. Gaucher's disease, it has been suggested that the differences may relate to the degree of processing undergone by the mutant enzymes and to the site of the mutation (9) . In contrast to the mutant enzyme in tissue from patients with the non-neuronopathic form of the disease (Type I), the enzyme in patients with neuronopathic (Type 11) form appears to be incompletely processed. Whether these observations are of relevance in Niemann-Pick disease must await a more detailed study of the mutant enzymes.
We are unable to confirm that sphingomyelinase in fibroblasts from patients with the chronic neuronopathic form of NiemannPick disease (Type C) is more responsive to activator than the normal enzyme as claimed by Christomanou (7) . Figure 3 shows that the normal and Niemann-Pick disease Type C fibroblasts respond in a similar fashion to the addition of varying amounts of highly purified activator; in addition, we are unable to confirm the low residual activity observed by this worker. One possible explanation for our inability to confirm these earlier observations is that there may be genetic heterogeneity in this group of disorders, a hypothesis supported by the marked diversity in clinical phenotypes (6, 19) and by the ultrastructural differences observed in cultured skin fibroblasts from these patients (8) . A more rigorous analysis of the hypothesis that the defect in Niemann-Pick disease Type C is due to an inherited deficiency in an activator protein must await the development of better analytical techniques for their detection and quantitation in a variety of tissue sources.
ABSTRACT. Previous studies have shown a reduction in mortality rate from 90% to zero when neonatal rats, inoculated with group B streptococci (GBS) were injected with type-specific IgM antibody. However, in those studies, the antibody was administered simultaneously with the bacteria and at the same site, unlike the situation which would exist if antibody was used clinically to treat established infection. In the present experiments, we administered antibody intraperitoneally at various intervals following intrathoracic inoculation of GBS. When antibody was administered immediately after, or up to 2 h following bacterial inoculation, all animals survived. When antibody administration was delayed for 4, 5, or 6 h, survival rates of 92,60, and 29% were observed. When antibody administration was delayed for more than 6 h, no survival occurred. Failure of antibody to protect animals from death
